Irinotecan (CPT-11): pharmacology and clinical applications. 1996

N Masuda, and S Kudoh, and M Fukuoka
Department of Internal Medicine, Osaka Prefectural Habikino Hospital, Japan.

UI MeSH Term Description Entries
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D009374 Neoplasms, Experimental Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms. Experimental Neoplasms,Experimental Neoplasm,Neoplasm, Experimental
D002166 Camptothecin An alkaloid isolated from the stem wood of the Chinese tree, Camptotheca acuminata. This compound selectively inhibits the nuclear enzyme DNA TOPOISOMERASES, TYPE I. Several semisynthetic analogs of camptothecin have demonstrated antitumor activity. Camptothecine
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077146 Irinotecan A semisynthetic camptothecin derivative that inhibits DNA TOPOISOMERASE I to prevent nucleic acid synthesis during S PHASE. It is used as an antineoplastic agent for the treatment of COLORECTAL NEOPLASMS and PANCREATIC NEOPLASMS. 7-Ethyl-10-hydroxycamptothecin,CPT 11,CPT-11,Camptosar,Camptothecin-11,Irinotecan Hydrochloride,Irrinotecan,NK012 Compound,SN 38,SN 38 11,SN-38,SN-38-11,7 Ethyl 10 hydroxycamptothecin,CPT11,Camptothecin 11,SN3811
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000972 Antineoplastic Agents, Phytogenic Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity. Antineoplastics, Botanical,Antineoplastics, Phytogenic,Agents, Phytogenic Antineoplastic,Botanical Antineoplastics,Phytogenic Antineoplastic Agents,Phytogenic Antineoplastics

Related Publications

N Masuda, and S Kudoh, and M Fukuoka
January 2005, Drug metabolism reviews,
N Masuda, and S Kudoh, and M Fukuoka
February 2008, Gan to kagaku ryoho. Cancer & chemotherapy,
N Masuda, and S Kudoh, and M Fukuoka
July 2000, Gan to kagaku ryoho. Cancer & chemotherapy,
N Masuda, and S Kudoh, and M Fukuoka
June 2002, Current cancer drug targets,
N Masuda, and S Kudoh, and M Fukuoka
April 1994, Gan to kagaku ryoho. Cancer & chemotherapy,
N Masuda, and S Kudoh, and M Fukuoka
August 2001, Clinical cancer research : an official journal of the American Association for Cancer Research,
N Masuda, and S Kudoh, and M Fukuoka
January 1996, European journal of cancer (Oxford, England : 1990),
N Masuda, and S Kudoh, and M Fukuoka
January 1996, Clinical and experimental pharmacology & physiology,
N Masuda, and S Kudoh, and M Fukuoka
January 1997, American journal of therapeutics,
N Masuda, and S Kudoh, and M Fukuoka
July 2003, Surgical oncology clinics of North America,
Copied contents to your clipboard!